Experimental Herpes Drug Clears Phase II Trial; CBCD Congratulates AiCuris

Aug. 16, 2012 - PRLog -- The Center for the Biology of Chronic Disease (CBCD) has learned that AiCuris, a pharmaceutical company that was formed in March 2006 as a spin-off of the Anti-Infectives Unit of BayerHealthCare, has completed a successful double-blinded, placebo-controlled phase II dose-ranging trial for the anti-herpes drug, AIC316.

The compound can be administered orally once daily for prophylaxis and suppression of the HSV-2 virus. AIC316 is a non-nucleosidic drug and acts via a novel mode of action targeting viral enzymes different from polymerases. In fact, AIC316 is an inhibitor of the viral helicase-primase of Herpes simplex 1 and -2 virus.

AiCuris’s experimental drug does not need to be activated inside the cell by a viral enzyme and therefore protects uninfected cells from infection.

Moreover, the very long halflife of the compound allows the drug to protect uninfected cells over extended periods of time, in contrast to the nucleoside analogues in the market. These features result in fast onset of action and powerful inhibition of viral shedding.

The CBCD congratulates AiCuris on the study’s success, and looks forward to a Phase III trial of AIC316.

Mike Evans, from the CBCD said, “I wish that more research in these areas was being funded…not just in terms of preventing herpes infection, but in terms of actually curing the disease. I think it is so important to take a look at all possibilities. Ground breaking science is hard to come by these days because the process for funding etc. is so slow. So, kudos to AiCuris and their research team!”

The CBCD would like to remind the public that AiCuris’s drug against herpes is still in the trial phase. It is also not intended to be a cure. In fact, there is no cure for a latent herpes (or other latent) viral infection.

The best way to guard against a latent herpes infection is to boost your immune system. Indeed, according to the CDC, herpes outbreaks tend to lessen over time. That’s why the CBCD would like to point out a herpes remedy that boosts the immune system and helps target the dormant, (latent) HSV virus.

“The key to your health is to reduce the level of latent viruses in your body to harmless levels.” – Dr. Hanan Polansky

The name of this herpes remedy is Gene-Eden-VIR. This scientifically designed, all-natural product helps the human body maintain low concentrations of the latent herpes virus.

By helping the body’s immune system take aim at the latent herpes virus, people can lower their risk of developing cold sores, fever blisters, or genital herpes symptoms. This is just one reason the CBCD believes Gene-Eden-VIR is an important product.

Gene-Eden-VIR is highly efficient at targeting the latent herpes virus; each ingredient was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent forms of both HSV-1 and HSV-2.

Gene-Eden-VIR is exceptionally safe. It has been on the market for over three years, and in that time, no side effects have been reported. Each capsule contains a patented formula of five all natural ingredients including selenium, camellia sinesis extract, quercetin, cinnamomum extract, and licorice extract. In addition, each bottle is GMP Certified.

Gene-Eden-VIR is sold online through the Gene-Eden website. Each bottle of Gene-Eden-VIR (a one month’s supply) costs just $34.99.

To learn more about Gene-Eden-VIR, the only product on the market today that helps the body target the latent herpes virus and that is scientifically backed by published material, visit http://gene-eden-kill-virus.com.

The Center for the Biology of Chronic Disease is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments for these diseases.

The CBCD published the “Purple” book entitled “Microcompetition with Foreign DNA and the Origin of Chronic Disease” written by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between the DNA of latent (chronic) viruses and the onset of chronic diseases.